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Abstract  29 
Francisellosis, induced by Francisella noatunensis subsp. orientalis (Fno), is an emerging bacterial 30 
disease representing a major threat to the global tilapia industry. There are no commercialised 31 
vaccines presently available against francisellosis for use in farmed tilapia, and the only available 32 
therapeutic practices used in the field are either the prolonged use of antibiotics or increasing water 33 
temperature. Recently, an autogenous whole cell-adjuvanted injectable vaccine was developed that 34 
gave 100% relative percent survival (RPS) in tilapia challenged with a homologous isolate of Fno. In 35 
this study, we evaluated the efficacy of this vaccine against challenge with heterologous Fno isolates. 36 
Healthy Nile tilapia, Oreochromis niloticus (~15g) were injected intraperitoneally (i.p.) with the 37 
vaccine, adjuvant-alone or phosphate buffer saline (PBS) followed by an i.p. challenge with three Fno 38 
isolates from geographically distinct locations. The vaccine provided significant protection in all 39 
groups of vaccinated tilapia, with a significantly higher RPS of 82.3% obtained against homologous 40 
challenge, compared to 69.8% and 65.9% with the heterologous challenges. Protection correlated with 41 
significantly higher specific antibody responses, and western blot analysis demonstrated cross-isolate 42 
antigenicity with fish sera post-vaccination and post-challenge. Moreover, a significantly lower 43 
bacterial burden was detected by qPCR in conjunction with significantly greater expression of IgM, 44 
IL-1 b, TNF-a and MHCII, 72 hours post-vaccination (hpv) in spleen samples from vaccinated tilapia 45 
compared to fish injected with adjuvant-alone and PBS. The Fno vaccine described in this study may 46 
provide a starting point for development a broad-spectrum highly protective vaccine against 47 
francisellosis in tilapia. 48 
 49 
Keywords: Inactivated vaccine, cross protection, immune response, Francisella noatunensis subsp. 50 
orientalis. 51 
 52 
 53 
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1. Introduction 54 
Francisella noatunensis subsp. orientalis (Fno) is a serious emerging bacterial pathogen affecting a wide 55 
range of ornamental and farm-raised cichlids globally [1-7]. Due to its fastidious nature, high 56 
infectivity (~ 23 CFU can induce clinical disease), wide host range, various routes of transmission, 57 
capacity to survive in multiple environments and co-existence with other pathogens, it has been 58 
highlighted as one of the major threats to the tilapia aquaculture industry, with mortalities of > 90% 59 
reported [8]. In tilapia farms, several strategies have been adopted to control francisellosis. The 60 
conventional practice of increasing the water temperature from 25 to 30°C was previously reported 61 
to inhibit the development of francisellosis in infected tilapia and other susceptible ornamental fish 62 
[2,9]. Treating with approved antibiotics like oxytetracycline (TerramycinÒ) and florfenicol 63 
(AquaflorÒ) for up to 10 days has also been reported to be effective [9-11]. Although the latter can 64 
potentially reduce fish mortality due to francisellosis [9], the use of antibiotics is not ideal as infected 65 
fish usually suffer from anorexia and there is a risk of the bacteria developing antibiotic resistance 66 
[12,13]. Currently no commercial prophylactic treatments are available for use against Fno in farmed 67 
fish. The broad emergence of Fno outbreaks globally has raised concerns of a potential francisellosis 68 
pandemic, thus efforts to develop protective vaccines against Fno have increased. Such vaccines 69 
should be safe, have a high level of efficacy, provide cross-protection, be cost effective and be easy to 70 
administer [14].  71 
In a previous study, the highest Relative Percent Survival (RPS) obtained in a vaccination trial 72 
in tilapia was 87.5 % using a live attenuated immersion vaccine [15]. However, live attenuated 73 
vaccines are not easily registered in all countries due to concerns relating to safety. Recently, an 74 
autogenous injectable whole cell adjuvanted bacterin developed using a virulent Fno isolate obtained 75 
from diseased tilapia farmed in Europe [16]. Following intraperitoneal (i.p.) vaccination and 76 
challenge with the homologous vaccine isolate, this vaccine stimulated protective antibodies and 77 
resulted in a high level of protection (RPS of 100%) [16]; however, cross protection of this vaccine 78 
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against heterologous isolates is unknown. Previous studies examining Fno genetic diversity using 79 
PCR-based typing or sequencing methods did not discriminate between Fno isolates from different 80 
countries, thus demonstrating a clonal behavioral pattern among these isolates [4, 17-19]. Minor 81 
antigenic differences between Fno isolates from distinct geographical regions have been highlighted 82 
in a previous proteomic study [20]. The capacity of the vaccine for cross protection, therefore, should 83 
be addressed. The aims of the current study were to investigate the efficacy of the recently developed 84 
injectable vaccine [16] by i.p. challenge with multiple Fno isolates from diverse geographical origins 85 
and evaluate the immune response to vaccination in Nile tilapia, O. niloticus (L). 86 
2. Materials and Methods  87 
2.1. Fish and rearing conditions 88 
Nile tilapia, O. niloticus, of mean weight 13 ± 0.8 g and an average length 10 ± 0.13 cm were obtained 89 
from a commercial tilapia farm in central Thailand, and transported to the research aquarium of Fish 90 
Vet Group Asia Ltd. (FVGAL), in Chonburi, Thailand. Upon arrival, the fish were transferred to 100 91 
L tanks in a recirculation system within a temperature-controlled room supplied with dechlorinated 92 
water, aerated with air stones and acclimated to their new conditions prior to the experiment. Water 93 
quality was maintained as follows: temperature 28°C ± 1, dissolved oxygen (DO) 6.5-7 mg/L, pH 7-94 
7.5, free ammonia £0.1 mg/L, nitrite £0.25 mg/L, nitrate £0.2 mg/L. The photoperiod in the room was 95 
maintained at 12 h light: 12 h dark with a 30 min transition. Fish were acclimated for 2 weeks and fed 96 
at a rate of 3% body weight per day with a commercial tilapia feed (Charoen Pokphand Foods Public 97 
Company Limited (CPF-PCL), Thailand). The Fno-free status of the tilapia was determined prior to 98 
commencing the vaccination study using samples of spleen and head kidney from six fish. 99 
Bacteriology analysis and a Francisella genus specific PCR targeting a partial sequence of the 16S 100 
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rRNA gene using primers listed in Table 1 were performed as previously described [2, 21]. Extraction 101 
of DNA from head kidney and spleen samples was performed using DNeasy Blood and Tissues kit 102 
(QIAGEN, Germany) following the manufacturer’s instructions. 103 
Table 1. Primers sequences used in the study 104 
Target 
Gene 
Oligo sequence (5’ - 3’) Genbank 
accession no. 
Product 
Size 
Annealing 
temperature 
Ref. 
Francisella spp. 
16S rRNA 
F11: TACCAGTTGGAAACGACTGT NR_074666.1 1140 pb 50 °C [21] 
R5: CCTTTTTGAGTTTCGCTCC     
Hypothetical  
protein gene 
F: CATGGGAAACAAATTCAAAAGGA JQ780323.1 85 pb 60 °C [22] 
R: GGAGAGATTTCTTTTTTAGAGGAGCT     
b-actin F: CCACACAGTGCCCATACTACGA 
R: CCACGCTCTGTCAGGATCTTCA 
XM_003443127 144 bp 60 °C [23] 
EF-1a F: GCACGCTCTGCTGGCCTTT 
R: GCGCTCAATCTTCCATCCC 
NM_001279647 250 bp 57 °C [24] 
IgM F: GGGAAGATGAGGAAGGAAATGA 
R: GTTTTACCCCCCTGGTCCAT 
KC708223 120 bp 57 °C [24] 
TNF-a F: CTTCCCATAGACTCTGAGTAGCG 
R: GAGGCCAACAAAATCATCATCCC 
NM_001279533 161 bp 60 °C [23] 
IL-1b F: TGCACTGTCACTGACAGCCAA 
R: ATGTTCAGGTGCACTTTGCGG 
XM_019365844 113 bp 57 °C [23] 
MHC-II F: ACTGACTGGGACCCGTCCAT 
R: ACAGGAAGCAGCCGCTTTTA 
XM_003459253 204 bp 57 °C [25] 
F: Forward primer, R: Reverse primer, bp: Base pair, Ref: Reference. 105 
2.2. Bacteria and culture conditions  106 
Bacterial isolates used in this study included three virulent isolates of Fno collected from separate 107 
francisellosis outbreaks in tilapia from three different geographical locations (Table 2). For challenge 108 
experiment, bacteria were cultured in cysteine heart agar supplemented with 1% bovine hemoglobin 109 
(CHAH) (Becton Dickenson BBL, USA), following previously published protocol [19]. A single 110 
colony from the agar plate was inoculated into Modified Muller Hinton broth (MMHB) (Difco, USA) 111 
containing 2% IsoVitaleX and 0.1% glucose as described by [2]. The Fno broth culture was incubated 112 
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for 18 h (mid log phase) at 160 rpm at 28°C followed by harvesting of the cells by centrifugation at 113 
3000 xg for 5 min and pellets were resuspended in sterile PBS to the appropriate optical density at 114 
OD600. The colony-forming units (CFU) per mL was estimated using a 6 x 6 drop plate method, 115 
following the published protocol [26] in conjugation with CHAH plates. Plates were incubated for 72 116 
h at 28°C to obtain colony count.  117 
Table 2. Fno isolates used in the challenge trial  118 
Isolate  
ID 
Designation Source Isolation 
year 
Reference 
Fno 1 AVU-STIR-GUS-F2f7 Red Nile tilapia (Europe) 2012 [19] 
Fno 2 NVI-5409 * Nile tilapia (Central America) 2006 Unpublished 
Fno 3 AVU-Fran-Cos1 Blue tilapia (North America) 2013 Unpublished 
AVU: Aquatic Vaccine Unit Bacterial Culture Collection, * Isolate supplied by Dr Duncan Colquhoun, 119 
Norwegian Veterinary Institute (NVI), Oslo, Norway.  120 
2.3. Fish vaccination and sampling  121 
Preparation of the inactivated-adjuvanted Fno vaccine was performed using the virulent Fno isolate 122 
(Fno 1), (Table 2) as described in [16]. Following a two-week acclimation period, fish (15 ± 0.2 g) were 123 
divided into four groups: a vaccination group (n = 260), an adjuvant-alone group (n = 260), a PBS 124 
control group (n = 260) and a naïve group (n = 20). The fish were stocked in 100 L recirculation tanks 125 
filled with chlorine-free water. The vaccination, adjuvant-alone and PBS control groups consisted of 126 
duplicate tanks with 130 fish each, whilst the naïve group consisted of a single tank of 20 fish (Figure 127 
1). Fish were starved for 24 h, anaesthetised with 10 % benzocaine in 100 % ethanol (Sigma, UK) and 128 
i.p. injected with 0.1 mL of vaccine, adjuvant-alone (Montanide, Seppic, France) or sterile PBS. The 129 
naïve group did not receive any treatments during the experiment. Fish were fed 3% of their body 130 
weight /day 24 h after injection and water quality was monitored throughout the trial. Fish were 131 
maintained at 28°C ± 1 for 30 days (840 degree days (dd)) and checked regularly for any 132 
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abnormalities. Prior to sampling, the fish were starved for 24 h and then euthanised with an overdose 133 
of benzocaine at 6, 24 and 72 h post-vaccination (hpv) and the spleen sampled from three fish/tank (n 134 
= 6) from each group. Tissue samples were stored in 1 mL of RNA later (Sigma, UK) at 4°C overnight, 135 
then the RNA Later was removed, and tissues were stored at -80°C until use. Blood samples were 136 
collected by lethal caudal vein puncture from five fish per tank at day zero (D0) and 30 days post-137 
vaccination (30 dpv) to measure IgM levels post-vaccination by enzyme-linked immunosorbent assay 138 
(ELISA). Blood was transferred to micro-centrifuge tubes, kept at 4°C overnight then centrifuged at 139 
3000 × g for 10 min. Serum was collected and kept at -20°C until used.  140 
 141 
 142 
 143 
 144 
 145 
 146 
 147 
 148 
 149 
 150 
 151 
Figure 1. Experimental design of the Francisella noatunensis subsp. orientalis (Fno) vaccination trial 152 
involving heterologous isolate challenge. dd: degree days, w: weeks, n: number of fish/group. 153 
 154 
 155 
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2.4. Fish challenge and sampling 156 
At 30 dpv (840 dd), fish in vaccinated, adjuvant-alone and PBS control groups (18 ± 0.5 g) were 157 
anaesthetised with benzocaine as described previously and each group was divided into three sub-158 
groups. Each group consisted of duplicate 100 L recirculation tanks with an integral UV system 159 
(TMC, UK) and 30 fish/tank (Figure 1). Each sub-group was i.p. injected with 0.1 mL of one of the 160 
three Fno isolates. The isolates included one homologous isolate (the vaccine isolate; i.e. Fno 1) and 161 
two heterologous isolates (Fno 2 and 3). The bacterial isolates were grown as described above. Doses 162 
of Fno isolates used in the challenge experiment are shown in Table 3. These doses were determined 163 
from a pre-challenge experiment (data not shown) and represent the bacterial concentration that 164 
induced 70% mortality (LD70) in the control fish. A sample of each bacterial inoculum was removed 165 
at the time of challenge and the dose (CFU) for each isolate was determined using the drop plate 166 
method [25].  167 
Table 3. Calculated dose of Fno isolates used in the challenge trial post-vaccination  168 
Isolates **   CFU/mL CFU/fish 
Fno 1 1.12 × 106 CFU/mL 1.12 × 105 CFU/mL 
Fno 2 1.23 × 106 CFU/mL 1.23 × 105 CFU/mL 
Fno 3 1.28 × 106 CFU/mL 1.28 × 105 CFU/mL 
** Optical density (OD600) set at 0.1 for all isolates. 169 
Fish were maintained for 15 days at 23 ± 2°C, examined four times per day and water quality was 170 
monitored. Fish received feed ad libitum, mortalities were removed, moribund fish were sampled, 171 
and occurrence of the disease was confirmed by bacteriology and PCR. The surviving fish at 15 days 172 
post challenge (15 dpc) were euthanised and blood was sampled for serum, and the relative percent 173 
survival (RPS) was calculated according to [27].   174 
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2.5. Enzyme-linked immunosorbent assay (ELISA)  175 
An indirect ELISA was performed to assess the specific IgM levels in serum of vaccinated, adjuvant-176 
alone and PBS control tilapia sera at day zero (D0), 30 dpv and 15 dpc with the three different Fno 177 
isolates according to [28].  178 
  179 
2.6. Immunoblotting 180 
The whole cell proteins of the three Fno isolates were resolved on 1D SDS-PAGE and a 1D western 181 
blot was performed as described [28]. Serum samples collected from fish at 30 dpv and 15 dpc from 182 
the different treatments were used to perform the immunoblotting to analyse cross-reactivity of the 183 
serum from vaccinated, adjuvant-alone and control fish 30 dpv (prior to challenge) with the 184 
homologous (Fno 1) and heterologous Fno isolates (Fno 2 and 3) and analyse cross reaction of the 185 
vaccine isolate (Fno 1) antigen with serum of fish from the different challenge groups at 15 dpc.  186 
 187 
2.7. RNA isolation and cDNA synthesis  188 
RNA was extracted from ~ 40-50 mg of the spleen samples collected from the vaccinated, adjuvant-189 
alone and PBS control groups at 6, 24, 72 hpv using TRI Reagent (Sigma, UK) following the 190 
manufacturer’s protocol. RNA samples were stored at -70 °C until further use. RNA quantity and 191 
quality were determined using the Nanodrop ND-1000 Spectrophotometer (ThermoFisher Scientific, 192 
UK). RNA integrity was checked by gel electrophoresis on 1.0% agarose gel. Potential DNA residues 193 
in RNA samples were removed using a DNA-free kit (Ambion, ThermoFisher Scientific, UK) 194 
according to the manufacturer’s instructions. The cDNA was synthesised using a High Capacity 195 
cDNA Reverse Transcription Kit (Applied Biosystem, USA) following the manufacturer’s protocol.  196 
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2.8. Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR)  197 
Spleen samples taken at 6 h, 24 h and 72 h post-vaccination were analysed by qRT-PCR to quantify 198 
the expression of immune related genes: IgM, TNF-a, IL-1β and MHC-III. All RT-qPCR assays were 199 
performed in white 96-well plates using an Eppendorf® Realplex2 Mastercycler gradient S instrument 200 
(Eppendorf, UK) with SYBR® Green I master mix (Thermo Scientific, UK) and primers (MWG 201 
Eurofins genomics, UK) as listed in Table 1. The RT-qPCR was performed in a 20 µL reaction mix 202 
consisting of 1x SYBR® Green I buffer, 0.3 µM from forward and reverse primers and 5 µL of the ten-203 
fold diluted cDNA. The cycling conditions were 94 °C for 15 s, 40 cycles of denaturation at 95 °C for 204 
30 s, annealing at the optimal temperature of each primer as indicated in Table 1 for 30 s and a final 205 
extension at 72°C for 1 min. Melting curve analysis included amplification at 60°C to 90°C with 0.1°C 206 
increments per second to evaluate the qPCR products specificity. Samples were run in duplicates and 207 
each qPCR run included RT negative (RT-) and non-template controls (NTC) (Milli-Q water only). 208 
Serial dilutions of a pool of all cDNA samples were prepared in nuclease free water including seven 209 
dilutions at 1:10, 1:20, 1:50, 1:100, 1:500, 1:1000 and 1:10000. The threshold cycle (Ct) values of these 210 
dilutions were plotted versus log concentration to generate a standard curve in the Realplex software 211 
V2.2 (Eppendorf, UK). The quality of the generated standard curve was evaluated using the slope 212 
curve and the correlation co-efficient (R2). The efficiency of the amplification of the qPCR targets was 213 
judged by the line slope following the equation, E= (10-1/slope) -1. The expression of the target genes in 214 
this study was normalised to the expression of b-actin and EF-1a. The fold change in the expression 215 
of the target genes in spleen samples of vaccinated and adjuvant-alone injected fish compared to the 216 
unvaccinated-control samples was calculated following the 2-DDCT method [29] using the Relative 217 
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Expression (REST©) Software [30]. All the primers used in this study were analysed for self-annealing 218 
using NCBI Blast sequence analyser [31].   219 
2.9. Quantification of bacterial load in survivor fish by quantitative real-time PCR (qPCR) 220 
Ten spleen samples were randomly collected from surviving fish in the different treatments 15 dpc 221 
and preserved in 95% ethanol (Sinopharm, China) for quantification of Fno load using real-time 222 
qPCR. DNA from 20 mg sub-samples of the spleen tissue were extracted using a DNeasy Blood and 223 
Tissue kit (Qiagen, UK), following the manufacturer`s protocol. Real-time qPCR was performed to 224 
quantify the Fno genomic load in copy numbers using a dilution range of 107 to 101 copies/ µL of DNA 225 
plasmid standard containing the unique gene (Fno FSC 771-hypothetical protein gene) previously 226 
described [32], using primers listed in Table 1, following the published qPCR protocol [22]. All 227 
samples were run in triplicate. After the run, analysis was performed using the default calculation of 228 
the threshold fluorescence (Ct value).  229 
 230 
2.9. Statistical analysis 231 
Data processing was performed using Microsoft Excel 2013, while GraphPad prism version 7 232 
(GraphPad software Inc., San Diego, CA, USA) was used to conduct pairwise Kaplan-Meier survival 233 
analyses [33] with subsequent Mantel-Cox log-rank tests applied to the mortality data to calculate the 234 
survival probabilities and to compare the survival distributions of fish in each experimental group. 235 
One-way ANOVA with a Tukey post hoc test was performed to analyse the differences in optical 236 
density (OD450) values representing antibody responses in serum samples and Fno load between the 237 
different treatments (vaccinated, adjuvant-alone and PBS control groups). In all cases a p-value of < 238 
0.05 was considered significant. The expression of the target genes in both vaccinated and adjuvant-239 
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alone injected fish samples was considered significantly different from that of the control samples 240 
when a p-value of <0.05 was obtained.   241 
 242 
3. Results 243 
3.1. Screening of tilapia for vaccination  244 
Tilapia tissues sampled prior to the experiment were negative for Fno when screened by bacteriology 245 
and PCR (Figure S1). 246 
 247 
3.2. Vaccine efficacy 248 
Mortalities started between 6- 8 days post-challenge (dpc) in the vaccinated groups and between 3-4 249 
dpc in the adjuvant-alone and PBS groups (Figure 2). The non-vaccinated fish had the lowest level of 250 
survival at 15 dpc with the three different Fno isolates. Fish injected with the adjuvant-alone had 251 
higher survival rates compared to fish injected with PBS, however these differences were not 252 
significant (p>0.05). The vaccinated fish demonstrated significantly higher levels of survival (p<0.001) 253 
than both the adjuvant-alone and the PBS injected groups post-challenge with the different Fno 254 
isolates (Table 4). The RPS values obtained in the vaccinated fish were 82.3%, 69.8% and 65.9%, while 255 
the adjuvant-alone group had RPS values of 15.6%, 20.9% and 18.2% post-challenge with Fno 1, Fno 256 
2 and Fno 3 isolates, respectively. No significant differences (p<0.05) were observed in level of survival 257 
obtained with the homologous isolate (Fno 1) compared to the heterologous isolates (Fno 2 and 3 258 
isolates) in the adjuvant-alone or PBS-injected groups. In the vaccinated group, however, fish 259 
challenged with the homologous isolate displayed significantly higher survival (p<0.05) than fish 260 
challenged with the heterologous isolates, which were not significantly different to each other 261 
(p>0.05) (Figure 3). 262 
 263 
 264 
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Table 4. Accumulated mortality in the different groups of fish after challenge (Average mortality % 265 
± SD of 2 parallel tanks holding 30 fish/tank/challenge group) 266 
Fno isolate Cumulative mortality in 
vaccinated fish 
(n= 60) 
Cumulative mortality in 
adjuvant-alone fish  
(n= 60) 
Cumulative mortality 
in PBS control fish  
(n= 60) 
Fno 1  13.3% (± 0.49) 63.3% (± 1.33) 75% (± 1.8) 
Fno 2 25 % (± 0.82) 60% (± 1.68) 73.3% (± 1.26) 
Fno 3 21.7 % (± 0.56) 56.7% (± 1.5) 71.7 % (± 1.74) 
            n: number of fish per challenge group  267 
 268 
 269 
 270 
 271 
 272 
 273 
 274 
 275 
 276 
 277 
 278 
 279 
Figure 2.  Kaplan-Meier (Log-rank Mantel Cox) representation of cumulative survival of tilapia 280 
fingerlings 15 dpc with 106 CFU/mL of Fno 1, Fno 2 and Fno 3. Each curve represents the average 281 
results of two parallel tanks holding 30 fish/tank/challenge group. The non-vaccinated, non-282 
challenged curve represents data from 1 tank with 20 fish. Groups that do not letters are significantly 283 
different (p<0.05). 284 
 285 
 286 
 287 
 288 
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Signs of Fno infection were clearly evident upon necropsy of recent mortalities and moribund fish, 289 
including ascites, enlargement of the spleen and head kidney with the presence of creamy nodules 290 
on these tissues (Figure 3). Detection of Fno in spleen of moribund fish from the different challenge 291 
groups was confirmed by bacteriology (Figure S2) and conventional PCR (Figure S3).  292 
 293 
 294 
 295 
 296 
 297 
 298 
 299 
Figure 3. Clinical signs of francisellosis in moribund (A) and recently dead (B) tilapia after 300 
heterologous i.p. challenge with three Fno isolates. (A) Ascites (dashed arrow); (B) enlargement of 301 
spleen (SP) and head kidney (HK) with appearance of white nodules on their surfaces.     302 
 303 
3.3. Specific antibody (IgM) response post-vaccination and challenge 304 
Vaccinated fish had significantly higher levels of specific antibody (IgM) (OD450 at 1:500 dilution) in 305 
their serum at 840 dd than the adjuvant or PBS injected fish as measured by ELISA. No specific 306 
antibody response was detected in fish prior to vaccination. Analysis of serum IgM levels post-307 
challenge with the three different Fno isolates (15 dpc) indicate that the vaccinated fish had 308 
significantly higher levels of antibody against Fno (p<0.05) compared to the adjuvant and PBS injected 309 
fish (Figure 4). In addition, the serum IgM level in the Fno 1 challenged fish was significantly higher 310 
(p<0.05) than that of fish challenged with Fno 2 or Fno 3 isolates. 311 
 312 
 313 
(A
 
(B) 
HK 
SP 
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 314 
 315 
 316 
 317 
 318 
 319 
 320 
 321 
Figure 4. Specific antibody response of tilapia following i.p. injection of vaccine, adjuvant-alone or 322 
PBS at 30 dpv (840 dd) and 15 dpc with multiple Fno isolates. Each bar represents the average serum 323 
IgM at OD450 of 10 fish/ treatment. [I] sera from fish before vaccination, [II] sera from fish 30 dpv, [III] 324 
sera from fish 15 dpc. The dashed line represents the cut-off (3X the average absorbance of the 325 
negative control (PBS)). Groups that do not share letters are significantly different (P < 0.05). dpv: 326 
days-post vaccination, dpc: days-post challenge.  327 
3.4. Immunoblotting 328 
The Fno isolates from the three geographical regions showed a similar profile when subjected to 1D 329 
SDS-PAGE (Figure 5A). Coomassie Blue and Silver staining revealed a conserved abundant protein 330 
band between 20-37 kDa. This band was strongly antigenic in different Fno isolates when serum 331 
sampled from the vaccinated fish 30 dpv was used (Figure 5A). The intensity of the immunoreactive 332 
region varied between the different antigen used, where the UK antigen (homologous or vaccine 333 
isolate) showed higher intensity than the other heterologous antigens. No immunoreactivity was 334 
observed with serum sampled at day zero (D0) or with serum from the adjuvant or PBS injected fish 335 
sampled at 30 dpv. The same immunoreactive band (i.e. 20-37 kDa) was also observed with the 336 
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vaccine isolate antigen (i.e. Fno 1) when blotted with serum from fish surviving the challenge with 337 
the different Fno isolates (Figure 5B). 338 
 339 
 340 
 341 
 342 
 343 
 344 
 345 
 346 
 347 
 348 
 349 
Figure 5. SDS-PAGE and Western blot analysis of whole cell lysates of Fno. Immunoreactivity of 350 
serum of vaccinated, adjuvant-alone and control tilapia 30 dpv against homologous and heterologous 351 
Fno isolates (A) and immunoreactivity of serum of survivor tilapia 15 dpc with the different Fno 352 
isolates in vaccinated, adjuvant-alone and control groups against Fno 1 (vaccine isolate) (B). 353 
Immunoreactive band on the blots is marked by black arrows and its corresponding protein band on 354 
the reference gels is marked by brackets. A1: 1D reference SDS PAGE gel stained with silver stain; M: 355 
marker; 1: Fno 1 isolate; 2: Fno 2 isolate; 3: Fno 3 isolate. A2: 1D reference SDS PAGE stained with 356 
Coomassie blue stain; 1: Fno 1 isolate; 2: Fno 2 isolate; 3: Fno 3 isolate. A3: 1D western blot showing 357 
the antigenic band observed using sera from PBS control (a); adjuvant-alone (b) and vaccinated tilapia 358 
(c) against whole cells lysate of Fno 1 (Lanes 1,4,7); Fno 2 (Lanes 2,5,8); Fno 3 (Lanes 3,6,9). d: western 359 
blot control sera; 10: positive control serum; 11: negative control serum; 12: TBS (Tris-buffer saline) 360 
(internal control). B1: 1D reference SDS PAGE stained with silver stain. M: marker; 1: Fno 1 isolate. 361 
B2: 1D reference SDS PAGE stained with Coomassie blue stain; 1: Fno 1 isolate. B3: 1D western blot 362 
showing the immunreactive band of the vaccine isolate (Fno 1) following blotting with sera from 363 
different challenge groups 15 dpc. e: sera from fish challenged with Fno 1 isolate in vaccinated group 364 
(Lane 1); adjuvant-only group (Lane 2); PBS control group (Lane 3); f: sera from fish challenged with 365 
Fno 2 isolate in vaccinated group (Lane 4); adjuvant-alone group (Lane 5); PBS control group (Lane 366 
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6); g: sera from fish challenged with Fno 3 isolate in vaccinated group (Lane 7); adjuvant-alone group 367 
(Lane 8); PBS control group (Lane 9). d: western blot control sera. 10: positive control serum; 11: 368 
negative control serum; 12: day zero serum; 13: TBS. 369 
3.5. Analysis of immune gene expression by RT-qPCR 370 
The relative expression of IgM, IL-1b, TNF-a and MHCII in tilapia RNA samples was first normalised 371 
against b-actin and EF-1a. The relative fold change in expression of these genes in RNA samples 372 
extracted from spleen of vaccinated and adjuvant-alone tilapia compared to the PBS injected fish is 373 
summarised in Table 5. At 6 hpv, there was a significant up-regulation of IL-1b in both vaccinated 374 
and adjuvant-alone groups with significantly higher expression in the vaccinated group (p < 0.001) 375 
than in the adjuvant-alone group (p <0.01). A significant up-regulation of TNF-a (p <0.001) and MHCII 376 
(p <0.01) was observed in the vaccinated group only at 6 hpv. At 24 hpv, a significantly higher 377 
expression of TNF-a and MHCII was observed in vaccinated fish (p <0.001) compared to the adjuvant-378 
alone and PBS-control fish (p < 0.01 and p < 0.05, respectively). Furthermore, MHCII was significantly 379 
down-regulated in the adjuvant-alone group (p < 0.01). At 72 hpv, a significant up-regulation of IgM, 380 
IL-1b, TNF-a and MHCII (p <0.01) was observed in vaccinated tilapia spleen samples accompanied 381 
with significant down-regulation of MHCII (p < 0.01) in the adjuvant-alone group. 382 
 383 
 384 
 385 
 386 
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Table 5. Relative expression of pro-inflammatory and immune related genes in spleen samples of vaccinated and adjuvant injected tilapia at 6 h, 24 h and 72 h 387 
post vaccination (hpv) compared to the non-vaccinated control group.  388 
Gene Treatment 6 hpv 24 hpv 72 hpv 
  Expression SE Expression SE Expression SE 
IgM 
Vaccinated 2.306 0.261-22.013 3.077 1.248-7.406 4.956 ↑↑ 2.384 - 11.362 
Adjuvant-alone 1.443 0.403-4.624 2.800 0.694 - 14.70 0.777 0.274 - 3.188 
IL-1b 
Vaccinated 7.884 ↑↑↑ 3.685 - 12.028 5.811 ↑↑↑ 1.911 - 11.435 4.977 ↑↑ 3.319 - 9.852 
Adjuvant-alone 5.761 ↑↑ 1.728 - 37.970 4.404 ↑↑ 1.713 - 11.199 4.269 ↑ 0.951 - 28.387 
TNF-a 
Vaccinated 2.467 ↑↑↑ 1.949 - 3.108 2.991 ↑↑↑ 2.164 - 3.998 4.539 ↑↑ 2.543 - 12.118 
Adjuvant-alone 1.188 0.876 - 1.659 1.473 ↑ 1.112 - 2.199 1.692 0.895 - 4.483 
MHCII 
Vaccinated 3.409 ↑↑ 1.854 - 4.927 4.190 ↑↑ 2.048 - 7.672 4.506 ↑↑ 2.815 - 6.063 
Adjuvant-alone 0.770 0.414 - 1.428 0.627 ↓↓ 0.435 - 0.861 0.395 ↓↓ 0.267 - 0.587 
  (↑ or ↓), (↑↑ or ↓↓) and (↑↑↑ or ↓↓↓) indicates significant up or down regulation relative to controls at (p < 0.05), (p < 0.01) and (p < 0.001), respectively. 389 
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3.6. Fno load in surviving fish post-challenge  390 
Quantification of the bacterial burden (copies/ µL) in the spleen samples from the different fish 391 
treatments showed significantly higher Fno loads (p<0.05) in the PBS control and adjuvant-alone 392 
groups compared to the vaccinated group after challenge with the different Fno isolates, respectively 393 
(Figure 6).  394 
 395 
 396 
 397 
 398 
 399 
 400 
 401 
 402 
 403 
Figure 6. Fno load (Log10 of mean copies/µL ±SD) quantified by qPCR in spleen of survivors after i.p. 404 
challenge with Fno 1, 2 and 3 isolates in the different treatment groups. Each bar represents average 405 
of Fno load of 10 spleen samples/treatment. Groups that do not share letters are significantly different 406 
(p < 0.05).  407 
 408 
4. Discussion 409 
Following the emergence of piscine francisellosis outbreaks worldwide, high mortality and serious 410 
economic losses have been reported in farm-raised tilapia due Fno infections. Efforts to develop 411 
potent, safe, cost-effective vaccines against Fno have therefore become a priority for the tilapia 412 
industry. The vaccine tested in this study conferred significant protection to tilapia (~15 g) challenged 413 
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with either homologous, or heterologous Fno isolates, compared to fish injected with adjuvant-alone 414 
or mock vaccinated with PBS. The results obtained are in agreement with a previous study using the 415 
same vaccine [16], which induced significant protection in tilapia, demonstrated by a RPS value of 416 
100% compared to 46.6% in the adjuvant-alone group post-challenge with the homologous Fno 417 
isolate. Furthermore, the RPS values obtained for vaccinated tilapia in this study were similar to those 418 
reported in tilapia vaccinated with a live-attenuated Fno vaccine after immersion challenge using a 419 
self-genotype Fno isolate that resulted in RPS of 68.8 % - 87.5 % [15]. Interestingly, the survival rates 420 
in the current study were higher than those obtained in zebrafish, Danio rerio, i.p. immunised with 421 
an Fno-outer membrane vesicle (OMVs)-derived vaccine and i.p. challenged with the same Fno 422 
vaccine isolate [34]. This suggests a weaker stimulation of the zebrafish immune system by OMVs 423 
compared to the adjuvanted whole cell vaccine used in the current study, although differences in 424 
susceptibility between tilapia and zebrafish to Fno may account for this variation.  425 
The difference in the level of protection against the homologous isolate (i.e. Fno 1 isolate) 426 
obtained in the current study (RPS 82.3%) and the previous study [16] (RPS 100%) may be attributed 427 
to differences in the genetic make-up and susceptibility of the fish used. Wild type Nile tilapia 428 
obtained from a commercial farm were used in the present study and therefore would have been 429 
exposed to stressors commonly associated with the farm environment, while hybrid red tilapia raised 430 
in an in-house aquatic research facility were used for the previous vaccine study [16]. Differences in 431 
bacterial inoculum were also used in the experimental challenge between the two experiments. A 432 
bacterial dose of 105 CFU/fish induced ~ 70 % mortality in control fish in the current study, while 103 433 
CFU/fish and 105 CFU/fish resulted in the same level of mortality in Nile tilapia and zebrafish, 434 
respectively [16, 34], which may have influenced the RPS values obtained in the different studies. A 435 
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higher level of protection is frequently obtained with live attenuated vaccines due to the induction of 436 
both a strong cell mediated immunity and humoral immunity [14]. The inactivated Fno bacterin used 437 
in our study not only appears to confer comparable protection to a live attenuated vaccine [15], but 438 
also it removes concerns relating to potential reversion to virulence and release of the live genetically 439 
modified organisms into the environment, a potential complication associated with live attenuated 440 
vaccines [35].  441 
It is of note that, the vaccine studied here stimulated a strong humoral immune response in the 442 
vaccinated fish, however, more studies are required to investigate the effect of this vaccine on 443 
cellular-mediated immunity. Generally, bacterial vaccines in fish aim to trigger a specific antibody 444 
response that provide protection against subsequent infections [36]. The antibody response post-445 
vaccination is a widely used parameter to examine vaccine efficacy in fish and other higher 446 
vertebrates when correlating with protection [35, 37, 38]. In the current study, a strong correlation 447 
between specific antibody production and the level of protection was observed. At 30 dpv, a 448 
relatively weak antibody response was observed in vaccinates, although it was significantly higher 449 
(p< 0.05) than in both adjuvant-alone and PBS control group fish. This corroborates previous results 450 
with this vaccine [16], this was, however, in contrast to weak mucosal or serum antibody responses 451 
obtained with the live attenuated Fno vaccine administered to tilapia by immersion or the OMVs-452 
derived Fno injectable vaccine trialed in zebrafish [15, 34]. In the present study, elevated levels of 453 
specific serum IgM were measured in all treatment groups at 15 dpc, when fish were challenged with 454 
the different Fno isolates, with significantly higher IgM values in the vaccinated fish. Furthermore, 455 
significantly higher Fno specific IgM levels were detected in the fish challenged with a homologous 456 
isolate (Fno 1), which correlated with significantly higher survival in this group compared to the fish 457 
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challenged with the heterologous Fno isolates (Fno 2 and 3). It is not surprising to get a higher level 458 
of protection in fish challenged with a homologous isolate as they are likely to elicit a stronger 459 
immune response than fish challenged with heterologous isolates. 460 
The protective mechanism of immunity against piscine francisellosis is yet to be determined. The 461 
correlation found between the survival of vaccinated fish and antibody levels in serum or mucus 462 
post-challenge in tilapia [15], zebrafish [34] and Atlantic cod [39] highlights the importance of 463 
antibody-mediated immunity in protection against Francisella infection in fish. This was also 464 
observed here in response to the current vaccine. Moreover, the specific antibody produced in 465 
response to vaccination/or infection with the majority of Gram-negative bacteria act synergistically 466 
with the complement system leading to a direct bactericidal effect on the invading bacteria or can 467 
assist phagocytic cells activity, mainly facilitated via Fc receptor bearing macrophage-like cells and 468 
NK cells to destroy the engulfed bacterial cells including intracellular bacteria [15]. This was 469 
previously demonstrated by the ability of antibodies in the serum of tilapia immunised with a live 470 
attenuated Fno vaccine to co-stimulate phagocytosis of Fno by head kidney derived macrophages 471 
(HKDM), which was hampered by either heat inactivated or naïve serum [15]. 472 
The antigenicity of the vaccine master seed may be a major factor in the efficacy of the vaccine 473 
against heterologous bacterial isolates [40]. Immunoblotting in the present study showed cross 474 
reaction between Fno isolates with sera obtained from vaccinated tilapia and also between the vaccine 475 
isolate (i.e. Fno 1) and tilapia serum post-challenge with either the homologous or heterologous Fno 476 
isolates. Taken together with the induced high survival rates (i.e. RPS), the cross-protection ability of 477 
the developed vaccine against challenge with multiple Fno isolates was highlighted. Further studies 478 
using other geographically distinct Fno isolates will give us more insights into the efficacy, and in 479 
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particular, establishment of the cross-protective nature of the developed vaccine. Future work may 480 
also include development and efficacy testing of bivalent or polyvalent Fno vaccines. 481 
A significant up-regulation of IgM transcription was noted in the spleen of immunised tilapia at 482 
72 hpv. This indicates that activation of B cells in response to vaccination is correlated with the 483 
increased serum IgM detected 30 dpv. Our results are consistent with the findings of an earlier study 484 
[34], where the authors reported an up-regulation of IgM at 7 dpv that was maintained to 21 dpv 485 
following i.p. immunisation of zebrafish with Fno-derived OMVs. There is lack of information 486 
regarding the role of cellular immunity against piscine francisellosis and most of our understanding 487 
is based on results from vaccine experiments with Francisella tularensis. It was reported that F. 488 
tularensis has the ability to trigger T-cell mediated immune responses, mainly antigen-specific IFN-γ 489 
responses [41, 42] and a strong cell-mediated immune response has also been suggested to prevent 490 
Francisella spp. infection in other vertebrates [43, 44]. In a recent study [34], a significant up-regulation 491 
of IFN-γ-1 transcription in zebrafish 24 h post-immunisation with Fno-derived OMVs was reported 492 
that remained up-regulated until 21 dpv. These authors suggested that IFN-γ prevents Fno from 493 
escaping from the zebrafish phagosomes containing Fno cells post-infection. Also, IL-12 and IL-17 494 
appears to drive a strong T-cell proliferation in Atlantic cod challenged with F. noatunensis subsp. 495 
noatunensis (Fnn) [45]. In the current study, the transcription of MHCII was significantly up-regulated 496 
in the spleen of vaccinated fish 6 hpv and at 24-72 hpv, where a 4.5-fold change was detected, while 497 
a significant down-regulation was observed in the adjuvant alone group. This suggests successful 498 
recognition of Fno cells in the vaccinated fish and presentation of the antigen by antigen presenting 499 
cells (APCs), which is a key event in triggering of a subsequent adaptive immune response [14].  500 
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The rapid activation of pro-inflammatory cytokines in response to the vaccine in the current 501 
study was evidenced by an early (6 hpv) significant up-regulation of IL-1β and TNF-a, which are 502 
produced primarily by activated macrophages in the spleen of the fish [46]. IL-1β is mainly involved 503 
in lymphocyte activation, leukocyte migration, phagocytosis and diverse bactericidal activities [47]. 504 
These findings agree with a previous study, where a significantly higher IL-1b expression was 505 
detected in kidney cells of adult zebra fish vaccinated with Fno-derived OMVs at 1 dpv compared to 506 
control fish [34]. Moreover, IL-1b expression was up-regulated in the splenic cells of Nile tilapia 24- 507 
96 hpc with Fno [48]. TNF-a is a well-known pro-inflammatory cytokine, associated with the killing 508 
of infected cells, inhibiting intracellular pathogen replication, apoptosis, up-regulating the 509 
transcription of various immune-related genes and recruiting leukocytes to the site of inflammation 510 
[48]. In contrast to the significant up-regulation of TNF-a transcription 6 hpv observed in the current 511 
study, down-regulation of this cytokine was noted in the head kidney of zebrafish vaccinated with 512 
Fno-derived OMVs 1-21 dpv [34]. While challenge with Fno successfully induced up-regulation of 513 
TNF-a 6-96 hpc in tilapia and 24 hpc and 48 hpc in adults and larval zebrafish, respectively [34, 48, 514 
49]. This suggests that whole cell Fno antigens, not found in the OMVs, may induced TNF-α 515 
stimulation by splenic leukocytes. Despite up-regulation of these cytokines in the adjuvant injected 516 
group, the fold change of their transcription was lower and of shorter duration than that obtained 517 
with the vaccine at 6, 24 and 72 hpv. Notably, up-regulation of TNF-a started earlier at 6 hpv in the 518 
spleen of vaccinated fish rather than in those receiving the adjuvant alone (24 hpv), implying that the 519 
response was induced by antigen and not a non-specific induction by the adjuvant. This result is 520 
supported by antibody responses detected by ELISA and western blot analyses in this study, and 521 
other studies [39], where the anti-Fno IgM in the sera of adjuvant-alone treated fish pre-challenge was 522 
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significantly lower in the ELISA and showed no recognition of specific protein bands in western 523 
blotting.  524 
Analysis of the bacterial burden in the vaccinated fish showed they did become infected, albeit 525 
with significantly lower bacterial loads than the adjuvant-alone and PBS control fish 15 dpc. Thus, 526 
the protection provided by the developed vaccine may be associated with the ability to enhance 527 
clearance and limit dissemination of the infection. This supports the application of using bacterial 528 
load quantification as a measure of vaccine efficacy against Fno. Future histological studies 529 
investigating the inflammatory and tissue-associated damage post-challenge between vaccinated and 530 
control tilapia would allow greater insights into the protection mechanisms of the developed vaccine 531 
at the tissue level. 532 
 533 
5. Conclusions 534 
The current study represents the first report of a protective oil-based adjuvanted inactivated 535 
injectable vaccine against multiple isolates of Fno from diverse geographical origins for Nile tilapia 536 
following injection immunisation and injection challenge. The significantly higher RPS in the 537 
vaccinated fish was correlated with significantly higher specific antibody responses, lower bacterial 538 
burden and greater expression of IgM, IL-1b, TNF-a and MHCII transcripts 72 hpv in comparison to 539 
the adjuvant alone or PBS control fish. This highlights the importance of antibody-mediated immune 540 
responses in the control of Fno infection in tilapia. In addition, the potential of the current vaccine to 541 
cross protect against different isolates of Fno was highlighted by immunoblotting. Taking into 542 
account the relatively short production cycle of tilapia in most of the tropical countries (6-9 months), 543 
a desirable vaccine must induce a significant long-term protection against Fno. Thus, future work will 544 
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investigate the duration of protection induced by the developed vaccine, and efficacy testing against 545 
more Fno isolates under field conditions. In conclusion, the whole-cell inactivated vaccine described 546 
in the present study may provide a starting point for developing a broad-spectrum highly protective 547 
vaccine against Fno outbreaks in tilapia. 548 
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 785 
Figure S1: Francisella genus specific 16S rRNA PCR for screening tilapia for the presence of Fno prior to 786 
vaccination. 1% agarose gel showing negative results for Fno in tested fish. M: 100bp Molecular marker; lane 787 
1-6: head kidney and spleen pool of 6 naïve tilapia; lane 7: Positive control; lane 8: negative control (Milli-Q 788 
water only). 789 
 790 
 791 
 792 
 793 
 794 
 795 
 796 
 797 
 798 
 799 
Figure S2: Grey, semi translucent and mucoid Fno colonies retrieved from spleen homogenate of moribund 800 
tilapia after i.p. challenge with Fno 1 (A), 2 (B) and 3 (C) isolates on CHAH.  801 
 802 
 803 
 804 
 805 
 806 
 807 
 808 
 809 
 810 
 811 
 812 
Figure S3: Francisella genus specific 16S rRNA PCR for detection of Fno in moribund fish and mortalities 813 
post-challenge with three different Fno isolates. 1% agarose gel showing amplicon of ~ 1140 bp. M: DNA 814 
ladder. Lanes 1 – 6: spleen of representative moribund fish (Lanes 1-3) and recently dead (Lanes 4-6) post the 815 
heterologous challenge with Fno 1 (Lanes 1,4), 2 (Lanes 2,5) and 3 (Lanes 3,6); lane 7: positive control; lane 816 
8: negative control (MQ- water only).   817 
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